ClinicalTrials.Veeva

Menu

Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas

Zhejiang University logo

Zhejiang University

Status

Enrolling

Conditions

Intraductal Papillary Mucinous Neoplasm

Treatments

Other: Observation

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

This is a prospective, open large cohort study to explore biomarkers for detecting early carcinogenesis of IPMN.

Full description

This prospective study was designed to explore biomarkers for detecting early carcinogenesis of IPMN. This study intends to prospectively and continuously enroll IPMN patients, and regularly collect biological samples including blood, urine, feces and saliva. We aimed to detect biomarkers which can predict the carcinogenesis of IPMN by multi-omics. The primary endpoint is the predictive accuracy of biomarkers for IPMN malignant transformation. The probability of IPMN malignant transformation , rates of surgical resection and survival after surgery are secondary endpoints.

Enrollment

5,000 estimated patients

Sex

All

Ages

Under 90 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • clinically diagnosed as IPMN;
  • without other malignant tumor;
  • agree to sign informed consent.

Exclusion criteria

  • with mental disorders which can affect cognition and cooperation;
  • with serious blood diseases or taking drugs that can affect peripheral blood

Trial design

5,000 participants in 1 patient group

Prospective IPMN cohort
Description:
Multi-omics analysis of 5000 prospectively collected samples.
Treatment:
Other: Observation

Trial contacts and locations

1

Loading...

Central trial contact

Tingbo Liang, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems